Search Menu
Photonics Media Photonics Buyers' Guide Photonics EDU Photonics Spectra BioPhotonics EuroPhotonics Industrial Photonics Photonics Showcase Photonics ProdSpec Photonics Handbook
More News
Email Facebook Twitter Google+ LinkedIn Comments

Axcan Acquires Photofrin Rights from QLT
May 2000
MONT SAINT-HILAIRE, Quebec, Canada, May 2 -- Axcan Pharma Inc. has signed an agreement to acquire worldwide rights to Photofrin -- a drug approved for use in photodynamic therapy for the treatment of certain cancers -- from QLT PhotoTherapeutics Inc. (QLT) of Vancouver.
Axcan's acquisition of the rights to the drug involves a stock subscription agreement under which QLT will purchase 1,283,333 shares of Axcan common stock for $19,250,000 (CDN), or $15 per share (CDN). The transaction between the two companies also involves an asset purchase agreement, which calls for QLT to sell, license or sub-license to Axcan all QLT's rights, title and interest in Photofrin for $39.25 million (CDN). This agreement includes the sale of QLT's European subsidiary, which owns the European registrations for Photofrin.

News & Features

Terms & Conditions Privacy Policy About Us Contact Us
back to top
Facebook Twitter Instagram LinkedIn YouTube RSS
©2019 Photonics Media, 100 West St., Pittsfield, MA, 01201 USA,

Photonics Media, Laurin Publishing
x We deliver – right to your inbox. Subscribe FREE to our newsletters.
We use cookies to improve user experience and analyze our website traffic as stated in our Privacy Policy. By using this website, you agree to the use of cookies unless you have disabled them.